
First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.
Picture this scenario: You walk into a pharmacy and find a new category of nonprescription medications near the pharmacy. These "Pharmacy Care OTCs" are available only in an outlet with a pharmacy, and are intended to treat chronic and asymptomatic conditions as well as other conditions that lend themselves to counseling by a pharmacist.



